Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in patients with female androgenetic alopecia, mesodermal injection of 0.5% minoxidil was more effective in increasing hair density and improving hairline height than topical 2% minoxidil, with comparable safety over 16 weeks.

In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.

This study observed that DDAIP-HCl enhanced the permeation of minoxidil through human cadaver skin, suggesting potential for improved treatment efficacy in male pattern hair loss.

This study found that incorporating 0.5% TPGS into topical minoxidil solutions enhanced hair growth in mice, although increasing TPGS to 2% decreased effectiveness.

This study found that co-applying Curcuma aeruginosa extract or essential oil with minoxidil significantly increased minoxidil's skin penetration in an ex vivo setting, suggesting an improved topical treatment strategy for androgenic alopecia with greater efficacy and the potential for lower minoxidil doses.

This study found that twice-daily application of 5% Minoxidil did not significantly impact hair growth in Sinclair minipigs over 27 days.

This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.

This study developed a novel LC-ESI-MS/MS method to quantify Minoxidil in pharmaceutical forms, finding it precise, accurate, and robust. It withstands excipient and degradant interference, although Minoxidil degrades under some stress conditions but remains stable thermally.

A woman with frontal fibrosing alopecia experienced unusual hair growth after using a specific topical lotion.

This study found that a cedrol nanoemulsion improved hair growth and bioavailability compared to an ointment, demonstrating enhanced efficacy in vitro and in vivo.

In this laboratory study on rabbits, the researchers observed that both FET and FHE fractions improved hair length and weight, but minoxidil still led to better results, highlighting the comparative effects of different treatments on hair growth over 28 days.

Minoxidil works better for female hair loss, but cyproterone reduces scalp oiliness and causes menstrual issues.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

In this study, intradermal injections of 0.5% minoxidil significantly improved hair growth and volume in women with female androgenetic alopecia compared to a placebo, with a good safety profile reported.

This study found that using minoxidil 2% as a mesotherapy injection showed more significant improvement in treating androgenetic alopecia in female patients than topical application.

This study observed that both intradermotherapy with 5% minoxidil and topical minoxidil application resulted in perceived improvements in hair density and thickness among patients with androgenetic alopecia, with no significant difference between the two groups.

This study found that a 2-deoxy-D-ribose gel stimulated hair follicle growth in mice with androgenic alopecia, showing effects similar to minoxidil without additional benefits from combining the two treatments.

This study observed that 2% minoxidil solution stopped hair loss and promoted new hair growth in 85% of female pattern androgenetic alopecia patients, while 2% progesterone solution achieved similar results in 71% of patients.

This study compared the effectiveness and safety of microneedling with PRP versus minoxidil and finasteride topical therapy in adult males with androgenetic alopecia, finding similar hair density improvements in both groups, though microneedling with PRP had a quicker onset of action.

This review discusses emerging treatments and mechanisms for alopecia, highlighting potential therapies like janus kinase inhibitors and advances in stem-cell technology, but reports no new experimental results.

This review discusses polycystic ovary syndrome, focusing on its primary features of ovulatory dysfunction and hyperandrogenism, and reports no new findings.

This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.

This descriptive literature review suggests that rosemary essential oil may stimulate hair growth in androgenetic alopecia with effects similar to 2% minoxidil, yet highlights the need for more robust clinical trials to confirm these findings and assess complementary methods like scalp massage and high-frequency treatment.

This study found that Soluplus and L-ascorbyl 2,6-dipalmitate nanoparticles may improve minoxidil's skin permeability through stable hydrophobic interactions, enhancing its potential for targeted skin application.

This study synthesized and characterized new 2-hydroxypyrrolidine/piperidine derivatives using FeCl₃·6H₂O as a catalyst, but it reports no biological or clinical results.

This review examines complementary and alternative medicine for alopecia and finds limited support from robust clinical trials, highlighting the need for standardized studies to evaluate efficacy and safety.

In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.

Minoxidil absorbs poorly through skin, with low risk of side effects at 1-2% concentration.

This study found that minoxidil-loaded niosomes with a Span 60 and cholesterol ratio of 1:2 significantly increased skin retention of minoxidil compared to control gel.